Dashboard
Manage Tickers

AZNCFASTRAZENECA PLC

Nasdaq astrazeneca.com


$ 1.55 (1.05 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 495.80 $ 5.12 (1.04 %)
DIA $ 393.71 $ 0.87 (0.22 %)
SPY $ 554.29 $ 3.18 (0.58 %)
TLT $ 92.56 $ 0.76 (0.83 %)
GLD $ 220.89 $ 2.94 (1.35 %)
$ 148.7
-- x --
-- x --
-- - --
$ 116.32 - $ 162.00
1,695
na
120.81B
$ 0.41
$ 7.06
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
AstraZeneca And Sanofi's Beyfortus (Nirsev...
01/02/2024 08:29:02

Beyfortus is anticipated to be available during the upcoming 2024-2025 RSV season.  

Core News & Articles
China Approves AstraZeneca's Imfinzi (Durv...
11/14/2023 09:53:47

Core News & Articles
AztraZeneca's Tagrisso Plus Chemotherapy E...
09/11/2023 08:31:40

The trial included patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-m...

Core News & Articles
AstraZeneca, Daiichi Sankyo's Datopotamab ...
09/11/2023 08:29:44

The trial included patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actiona...

Core News & Articles
The FDA Issued A Complete Response Letter ...
09/06/2023 08:24:25

The CRL did not request additional analysis or reanalysis of the Phase 3 CHAMPION-NMOSD trial data and did not raise concerns...

astrazeneca-abandons-blood-cancer-cardiovascular-programs-amid-portfolio-prioritization
AstraZeneca Abandons Blood Cancer, Cardiov...
07/28/2023 17:51:17

Earlier today, AstraZeneca plc (NASDAQ: AZN) 

astrazeneca-q2-earnings-beat-consensus-despite-zero-covid-19-vaccine-sales-stock-shoots-up
AstraZeneca Q2 Earnings Beat Consensus Des...
07/28/2023 12:46:39

AstraZeneca Plc's (NASDAQ: AZN) unit Alexion has 

Core News & Articles
Ionis Has Expanded Its Existing Collaborat...
07/28/2023 11:08:39

Ionis and AstraZeneca will continue to jointly develop and commercialize eplontersen in the U.S. The companies are successfully...

Core News & Articles
Alexion, AstraZeneca Rare Disease Agreed T...
07/28/2023 07:35:25

https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-enters-gene-therapy-agreement-with-pfizer.html

Core News & Articles
AstraZeneca's Soliris (Eculizumab) Has Bee...
07/27/2023 08:15:42

astrazeneca-sanofis-respiratory-syncytial-virus-treatment-scores-fda-approval-to-prevent-infection-in-infants
AstraZeneca-Sanofi's Respiratory Syncytial...
07/18/2023 13:07:02

The FDA approved AstraZeneca Plc (NASDAQ:

astrazeneca-shares-under-pressure-on-some-adverse-events-in-late-stage-lung-cancer-drug-trial
AstraZeneca Shares Under Pressure On Some ...
07/03/2023 09:50:08

AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato...

astrazenecas-imfinziimjudo-combo-shows-sustained-overall-survival-benefit-at-four-years-in-liver-cancer
AstraZeneca's Imfinzi/Imjudo Combo Shows S...
06/29/2023 17:39:45

AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imj...

astrazeneca-seeks-expanded-use-for-soliris-as-first-targeted-therapy-for-pediatric-patients-with-autoimmune-neuromuscular-disease
AstraZeneca Seeks Expanded Use For Soliris...
06/26/2023 12:28:58

The European Union has reco

why-are-pieris-pharmaceuticals-shares-tanking-today
Why Are Pieris Pharmaceuticals Shares Tank...
06/21/2023 13:41:04

Pieris Pharmaceuticals Inc (NASDAQ: PIRS) announced that partner AstraZeneca plc (NASDAQ: AZN) decided to discontinue and cease...

astrazeneca-mulls-china-business-unit-spin-off-amid-geopolitical-tensions
AstraZeneca Mulls China Business Unit Spin...
06/20/2023 12:23:28

European drugmaker AstraZeneca plc (NASDAQ: AZN) is reportedly drafting a plan to spin off its China business, and listing a se...

Core News & Articles
The FDA Has Granted Priority Review To Ast...
06/12/2023 08:29:34

The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is during the fourth quarter of 2023.

astrazenecas-add-on-treatment-with-standard-care-improves-hemoglobin-levels-in-rare-blood-disorder
AstraZeneca's Add On Treatment With Standa...
06/09/2023 12:44:45

AstraZeneca Plc (NASDAQ: AZN) 

astrazeneca-inks-over-2b-agreement-for-cell-therapies-targeting-diabetes
AstraZeneca Inks Over $2B Agreement For Ce...
06/09/2023 12:14:54

AstraZeneca plc (NASDAQ: AZN) has entered into a

unanimous-support-for-astrazeneca-and-sanofis-nirsevimab-next-generation-rsv-treatment-on-the-horizon
Unanimous Support for AstraZeneca and Sano...
06/09/2023 12:07:06

The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanof...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)